Recent Updates
Recently added Catalysts

TC-3 mixed with Botox

Phase 1

Interstitial Cystitis | Unknown | Other |UroGen Pharma Ltd.|Last Updated: Apr 12, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment15
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01997983Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC PatientsPHASE1 COMPLETED 15Nov 1, 2013Aug 1, 2015Apr 12, 20161 Israel
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
VAS score
week 12

Change from baseline in Visual Analog Scale (VAS) score for bladder pain measured at week 12 post BTX+TC-3 instillation.

Secondary Endpoints
Number of voids in 24hour period
12 weeks post instillation
NUmber of urge episodes in 24-hour period
12 weeks post instillation
number of nocturnal voids in one night
12 weeks post instillation
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TC-3 Gel with BotoxEXPERIMENTALopen label observational study
Interventions
NameTypeDescription
TC-3 Gel mixed with Botox (BTX)DEVICETC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Subject diagnosed with Interstitial Cystitis/PBS. 2. Subject has signed Informed Consent Form and is willing and able to abide by the protocol. 3. Subject has IC Symptom index (of IC Symptom and Problem Questionnaire) score of 12-20 points. 4. Subject has IC Problem index (of...

Countries:Israel
Unlock Eligibility Criteria